Inovio Pharmaceuticals, Inc.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. carries a market capitalization of 90.58M, placing it among publicly traded companies globally. Its enterprise value stands at 61.90M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Inovio Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. has 82.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Inovio Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -409.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -114.64, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 117.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Inovio Pharmaceuticals, Inc.'s stock has declined approximately 63.47% over the past 52 weeks. The 50-day moving average sits at 1.17, while the 200-day moving average is 1.30.

Over the twelve months ended June 30, 2026, Inovio Pharmaceuticals, Inc. generated - - in revenue and converted that into -67.43M in net income, yielding earnings per share of -0.99. EBITDA reached -76.25M, while operating income came in at -79.26M.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. holds 36.67M in cash and equivalents against 8.00M in total debt, resulting in a net debt position of -31.53M. Total book value stands at 4.37M, with working capital of -1,810.00 providing operational flexibility.

Inovio Pharmaceuticals, Inc. produced -80.58M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -195,395.00 in capital expenditures, free cash flow totaled -80.78M - equivalent to -1.19 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -108.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -77.47, meaning Inovio Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Inovio Pharmaceuticals, Inc.'s most recent stock split took place on January 26, 2024 with a 12:1 split ratio.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. has an Altman Z-Score of -56.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.